To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
GALC Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GALC, including heterozygous and homozygous R101X, heterozygous and homozygous Y541S, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2025
Rab21 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in Rab21, including- -S71R (heterozygous and homozygous) - in development, estimated late 2026
- -Knockout (homozygous) - in development, estimated late 2026
RAB32 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in RAB32, including - -S71R (heterozygous and homozygous) - in development, est late 2025
- -Knockout (homozygous) - in development, est late 2025
SCARB2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SCARB2, including- -R424* (heterozygous and homozygous) - in development, est late 2025
- -W146Sfs*15 (heterozygous and homozygous) - in development, est late 2025
- -Knockout (homozygous) - in development, est late 2025
Parkin Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PRKN, including - -R42P (heterozygous and homozygous)
- -T240M (heterozygous and homozygous)
- -R275W (heterozygous and homozygous)
- -P437L (heterozygous and homozygous)
DJ-1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PARK7 (DJ-1), including:- -D194A (heterozygous and homozygous)
- -L166P(heterozygous and homozygous)
SPTSSB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered homozygous knockout of SPTSSB.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2026
STING1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous knockout of STING1. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: Late 2026
TLR2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous knockout of TLR2.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD).This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated availability: late 2026
OGA Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations heterozygous and homozygous knockout of OGA. This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Anticipated Availability: Q4 2026
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic